文献速递胸部肿瘤

Neotorch研究最终分析:围手术期特瑞普利单抗联合化疗治疗Ⅱ/Ⅲ期可切除非小细胞肺癌

Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2026-10-26

Neotorch研究最终分析纳入501例中国Ⅱ/ⅢA、ⅢB(N2)期可切除NSCLC患者,随机接受围手术期特瑞普利单抗或安慰剂联合化疗。中位随访48.2个月,特瑞普利单抗组EFS显著改善(分层HR 0.52,95%CI 0.39-0.68,分层P<0.0001),MPR率47%对9%(P<0.0001),OS亦显著延长(HR 0.66,95%CI 0.49-0.89,P=0.0072),安全性可控。

要点

  • 围手术期特瑞普利单抗联合化疗显著改善Ⅱ/Ⅲ期可切除NSCLC的EFS(HR 0.52)。
  • MPR率47%对9%,组间差异有统计学意义和临床意义。
  • OS显著延长(HR 0.66,P=0.0072),安全性无新信号。

核心结论

  • 围手术期特瑞普利单抗联合化疗在可切除Ⅱ/Ⅲ期NSCLC中显示持久的EFS、MPR和OS获益,安全性可控。

研究设计与样本

  • 随机对照研究,纳入中国初治可切除Ⅱ期或ⅢA、ⅢB(N2)期NSCLC患者501例,特瑞普利单抗组250例、安慰剂组251例。
  • 新辅助治疗3周期、辅助治疗1周期,之后特瑞普利单抗或安慰剂单药维持治疗最多13周期。
  • 主要终点为研究者评估的Ⅲ期患者EFS和盲法独立病理审阅的MPR,以及Ⅱ和Ⅲ期患者总体结局。

主要发现

  • 最终分析中位随访48.2个月,特瑞普利单抗组研究者评估EFS显著改善,分层HR 0.52(95%CI 0.39-0.68,分层P<0.0001)。
  • 特瑞普利单抗组中位EFS未达到,安慰剂组为20.2个月。
  • MPR率组间差异有统计学意义和临床意义(47%对9%,P<0.0001)。
  • 特瑞普利单抗组OS延长有统计学意义(HR 0.66,95%CI 0.49-0.89,P=0.0072),两组中位生存均未达到。
  • 安全性特征与 interim analysis 一致,未发现新的安全性信号。

关键数值与推荐

  • EFS:分层HR 0.52(95%CI 0.39-0.68,分层P<0.0001),中位EFS特瑞普利单抗组未达到、安慰剂组20.2个月。
  • MPR率:47%对9%(P<0.0001)。
  • OS:HR 0.66(95%CI 0.49-0.89,P=0.0072),两组中位生存均未达到。

临床怎么用

  • 对可切除Ⅱ/ⅢA、ⅢB(N2)期NSCLC,可考虑围手术期特瑞普利单抗联合化疗作为治疗选择。
  • 治疗期间关注EFS、MPR和OS获益,并按最终分析的安全性特征进行管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable stage Ⅲ non-small-cell lung cancer (NSCLC). In this article, we report the overall final analysis results of the stage Ⅱ and Ⅲ patients in this study. PATIENTS AND METHODS: Eligible patients with treatment-naïve resectable stage II or stage IIIA, IIIB (N2) NSCLC were randomly assigned to receive toripalimab or placebo plus chemotherapy as neoadjuvant treatment (three cycles), adjuvant treatment (one cycle), and toripalimab or placebo monotherapy as maintenance treatment (up to 13 cycles). The primary endpoints of this study were EFS assessed by investigators and MPR evaluated by blinded independent pathologic review in stage Ⅲ patients, as well as the overall outcome in stage Ⅱ and Ⅲ patients. RESULTS: A total of 501 patients in China were included in this randomized study (toripalimab arm: N = 250, placebo arm: N = 251). Baseline characteristics were generally balanced between the 2 arms. At the final analysis (median follow-up of 48.2 months), the investigator-assessed EFS was significantly improved in the toripalimab arm, with a stratified hazard ratio (HR) of 0.52 [95% confidence interval (CI) 0.39-0.68, stratified P < 0.0001]. The median EFS in the toripalimab arm was not reached, while it was 20.2 months in the placebo arm. The between-arm difference in MPR rate was statistically significant and clinically meaningful (47% compared with 9%, P < 0.0001). Overall survival (OS) prolongation was also statistically significant in the toripalimab arm (HR 0.66, 95% CI 0.49-0.89, P = 0.0072), with median survival not reached in either arm. The safety profile was consistent with that of the interim analysis, with no new safety signals identified. CONCLUSIONS: Perioperative toripalimab plus chemotherapy demonstrated durable and significant benefits in EFS, MPR, and OS in patients with resectable stage Ⅱ and Ⅲ NSCLC, with a manageable safety profile. GRAPHICAL ABSTRACT.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Li ZM, Wu L, Wang WX, et al. Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer. Ann Oncol. 2026. PMID: 42933639. doi:10.1016/j.annonc.2026.10.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。